Paul L. Berns, Director at Jazz Pharmaceuticals plc (JAZZ), sold 8,982 shares at $149.28 ($1.4M) on 2020-11-04, disclosed to the SEC on 2020-11-04.
Open-market sale of $1.4M JAZZ by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $147.44 | 466 | $69K | 5.1% |
| 2 | $147.44 | 466 | $69K | 5.1% |
| 3 | $149.28 | 400 | $60K | 4.4% |
| 4 | $150.90 | 3,825 | $577K | 42.7% |
| 5 | $150.90 | 3,825 | $577K | 42.7% |
| Total | $150.47 avg | 8,982 |
| $1.4M |
| 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |